INTRODUCTION
============

Intestinal barrier dysfunction and bacterial translocation (BT) are common in patients with advanced liver disease, and there is strong evidence that gut-derived bacterial products play a central role in the onset of acute liver injury and progression to chronic liver disease ([@b22-bt_27-222]; [@b5-bt_27-222]). In fact, many severe complications of cholestasis and cirrhosis are aggravated by BT including hepatic encephalopathy, hepatorenal syndrome, as well as hepato-cardiac syndrome ([@b2-bt_27-222]; [@b16-bt_27-222]). This novel aspect of disease pathophysiology suggests that therapeutic strategies should aim at restoring the host intestinal mucosal barrier in cholestasis and cirrhosis.

Severe cholestasis leads to vitamin D depletion and vitamin D deficiency promotes cholestatic liver injury ([@b17-bt_27-222]; [@b7-bt_27-222]; [@b12-bt_27-222]). The active form of vitamin D, *1,25(OH)~2~D~3~*, has an antiproliferative and antifibrotic effect on hepatic stellate cells and vitamin D inhibits development of liver fibrosis in an animal model ([@b14-bt_27-222]; [@b1-bt_27-222]). However, the effect of vitamin D on intestinal barrier dysfunction in liver cholestasis has not been studied in detail. As a regulator of Toll-like receptor 4, vitamin D preserves intestinal epithelial barrier function and the vitamin D/vitamin D receptor (VDR) pathway has been shown to have intestinal protective effects in inflammatory bowel disease by inhibiting intestinal epithelial apoptosis ([@b3-bt_27-222]; [@b19-bt_27-222]). This study was designed to test whether vitamin D therapy improves intestinal dysfunction in cirrhosis.

MATERIALS AND METHODS
=====================

Animals
-------

Male Sprague-Dawley rats, weighing 200 to 250 g, were used in this study after 7 days of acclimatization. Rats were housed in an animal facility on a 12-h light/dark cycle, and were allowed access to standard rat chow and water ad libitum. All procedures were carried out in accordance with the "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985).

Liver fibrosis models
---------------------

Liver fibrosis was induced by administering subcutaneous injections of sterile 50% CCl~4~ (a mixture of pure CCl~4~ and olive oil, 0.3 mL/100g body weight) twice a week for 10 weeks. *1,25(OH)~2~D~3~* (5 µg/mL), at a dose of 0.5 µg/100 g body weight, was injected simultaneously. A twice-weekly *1,25(OH)~2~D~3~* dosing regimen was chosen to prevent development of hypercalcemia ([@b1-bt_27-222]).

Animals were divided into the following four groups (n=8): the sham group, *1,25(OH)~2~D~3~* treatment group, CCl~4~ treatment group, and combined treatment (CCl~4~ and *1,25(OH)~2~D~3~*) group.

At the end of the treatment period, rats were anesthetized and blood samples were obtained by cardiac puncture. Samples of mesenteric lymph nodes (MLNs), liver, and spleen were also collected under sterile conditions and then the rats were euthanized. Distal ileum and colonic tissue samples were obtained and snap-frozen in liquid nitrogen for subsequent analysis. Other tissue samples were immediately fixed in 10% formalin for histochemical studies.

Biochemical assessment
----------------------

Blood samples were centrifuged and serum was collected for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), and albumin (ALB) assay at a special clinical laboratory.

Bacterial translocation (BT)
----------------------------

Under sterile conditions, blood samples were cultured aerobically and anaerobically for 7 days. Samples of MLNs, liver, and spleen were placed in tubes containing thioglycolate broth and homogenized and subjected to aerobic/anaerobic culture for 3 days. Bacterial growth was considered evidence of BT. The translocation ratio was calculated as the ratio of the total number of positive cultures of blood, MLNs, and organs to the total number of cultures of blood, MLNs, and organs tested in each group.

Histopathology
--------------

Histopathological examination was performed with light microscopy using 4 µm hematoxylin and eosin (H&E) stained tissue sections. Hepatic fibrosis was also evaluated with Masson Trichrome staining. Histopathological examinations were performed by a pathologist who was blinded to the study design.

Intestinal mucosal permeability
-------------------------------

We used a modification of a previously reported method to assess intestinal mucosal permeability ([@b10-bt_27-222]). In this method, EZ-link^®^ Sulfo-NHS-Biotin, molecular size 443 Da (Pierce Chemical Co., Rockford, IL, USA; Thermo Scientific Inc., Waltham, MA, USA) was used as a molecular tracer. In brief, a blunt-ended 18-gauge needle was gently inserted into the proximal colon that had been clamped using vessel cannulation forceps to grasp the needle through the colonic tissue. A sufficient amount of biotin tracer was injected into the lumen of the colon for 3.5 min to make it expand slightly. Following this, the region of colon in contact with the needle was removed (1 cm). The tissue was then washed three times in PBS and subjected to cryo-embedding, sectioning, and immunostaining by incubating with a 1:500 dilution of streptavidin conjugated to Alexa 488 (1:500; Molecular Probes, Eugene, OR, USA) for 30 min.

Intestinal permeability was also measured by fluorescein isothiocyanate (FITC)-dextran (FD-4)-based intestinal permeability methods as previously described ([@b9-bt_27-222]). A 5-cm segment of the ileal sac was ligated beginning at 3 cm proximal to the ileocecal valve, then PBS (pH 7.4) containing 25 mg/mL FD-4 was injected into the ileal sac to make it expand slightly. After 30 min, a blood sample (100 µL) was collected from the portal vein and immediately diluted with 1.9 mL of 50 mmol/L Tris (pH 10.3) containing 150 mmol/L sodium chloride. The diluted plasma was centrifuged at 3000 ×g for 10 min, and plasma FD-4 concentrations were determined using fluorescence spectrophotometry (ThermoFisher Scientific, Waltham, MA, USA) at an excitation wavelength of 480 nm and an emission wavelength of 520 nm.

Immunofluorescence
------------------

Sections of small intestinal and colonic tissue from all rats sacrificed for immunofluorescence staining were frozen in tissue freezing medium prior to cryo-embedding and sectioning. For immunostaining, 6 µm frozen sections were fixed in cold acetone for 15 min. Thereafter, tissues were permeabilized with 0.2% Triton X-100 in PBS for 20 min, and blocking was achieved by incubation with 5% goat serum. Incubation with primary antibodies ZO-1 (1:100; Zymed Laboratories Inc., San Francisco, CA, USA), occludin (1:200; Zymed Laboratories Inc.), heme oxygenase-1 (HO-1) (1:500; Abcam Inc., Cambridge, MA, USA) and proliferating cell nuclear antigen (PCNA) (1:500; Abcam Inc.) was performed overnight at 4°C. After three washes with PBS, the sections were incubated with Alexa 594-conjugated secondary antibodies (1:500; Molecular Probes) at room temperature for 2 h in the dark. Sections were then washed and mounted under coverslips using ProLong Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA, USA). The stained sections were visualized and photographed using a Nikon fluorescence microscope (NIS-Elements systems; Nikon Instruments Inc., Melville, NY, USA).

Epithelial proliferation and TUNEL assay
----------------------------------------

Crypt cell proliferation rate was calculated as the ratio of the number of crypt cells positive for PCNA labeling to the total number of crypt cells. The number of proliferating cells per crypt was defined as the mean of proliferating cells in 10 crypts ([@b4-bt_27-222]). The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP Nick-End Labeling (TUNEL) assay was used to detect fragmented DNA in situ on cryosections using an In Situ Cell Death Detection Kit-FITC (Roche Applied Science, Mannheim, Germany) and following the manufacturer's instructions. Double-labeling of TUNEL with PCNA was employed. For TUNEL assay, in each examination, 1000 to 1500 cells from small intestinal villi without crypts were counted. Based on these observations, apoptotic index (AI) was defined as the count of positively stained cells in villi without crypts per 100 cells ([@b21-bt_27-222]).

BrdU labeling and enterocyte migration
--------------------------------------

Standard 5-bromodeoxyuridine (BrdU) labeling reagent (Zymed Laboratories) was injected intraperitoneally at a dose of 50 mg/kg body weight 6 h before the animals were euthanized. Cell proliferation was assessed using biotinylated sheep polyclonal anti-BrdU antibody (1:500; Abcam Inc.). For ease of assessment, the villus was divided into base, middle, and top parts. Quantification of BrdU+ cells along the crypt-- villus axis was performed.

Western blotting
----------------

Frozen biopsies were disrupted with a tissue lyser in radioimmunoprecipitation assay buffer, and total protein was quantified using the bicinchoninic acid (BCA) method. Equal concentration of proteins was loaded into a 6--10% sodium dodecyl sulfate-polyacrylamide gel and then electrotransferred. Membranes were blocked, incubated with the corresponding primary antibody at 4°C overnight, and then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG anti-body (1:20000; Sigma-Aldrich, St. Louis, MO, USA) for 1 h at room temperature. After washing, the immune complexes were detected using ECL detection reagent (Pierce Chemical Co., Thermo Scientific). Primary antibodies used for western blotting were: ZO-1, occludin, HO-1, GADPH (1:1000; CST Inc., Cell Signaling Technology, Danvers, MA, USA). Protein expression of each molecule was expressed as relative intensity and normalized to GADPH.

Oxidative stress measurement
----------------------------

Protein concentration of tissues was assayed using a BCA assay kit from (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Lipid peroxidation was evaluated by measuring the production of malondialdehyde (MDA) with a lipid peroxidation MDA assay kit (Beyotime, Shanghai, China). Glutathione (GSH) was assayed by using the spectrophotometric method, which is based on the use of Ellman's reagent.

Statistical analysis
--------------------

Data are reported as the mean ± 1.0 SD when appropriate. Differences in BT occurrence between groups were compared by using Fisher's exact test. Differences between means were evaluated by one-way ANOVA test. Bonferroni test was applied for pairwise comparison of every combination of group pairs. All analyses were conducted in SPSS13.0 software (SPSS Inc., Chicago, IL, USA). Statistical significance was set at *p*\<0.05.

RESULTS
=======

Effect of *1,25(OH)~2~D~3~* on CCl~4~-induced hepatotoxicity
------------------------------------------------------------

HE-staining showed that control rats showed no pathological changes in the liver. Liver tissues in the CCl~4~ group showed degenerative changes and centrilobular necrosis; hepatocytes showed ballooning, lipid droplet deposition, and inflammatory cell infiltration, as well as collagen deposition ([Fig. 1A](#f1-bt_27-222){ref-type="fig"}). Obvious bridging fibrosis was also observed in the CCl~4~ group, which showed periportal collagen deposition and staggered fibrosis formation, forming a large number of false lobules ([Fig. 1B](#f1-bt_27-222){ref-type="fig"}). However, pathological liver damage and fibrosis were mildly diminished in *1,25(OH)~2~D~3~*-treated animals.

The levels of serum ALT, AST, and AKP were higher in CCl~4~-treated rats, while ALB levels were lower. In *1,25(OH)~2~D~3~*-treated animals, serum ALT, AST, and AKP levels decreased compared with CCl~4~-treated animals; ALB levels however were increased ([Fig. 1C](#f1-bt_27-222){ref-type="fig"}). Additionally, serum 25-OH vitamin D concentrations were significantly lower (*p*\<0.05) in the CCl~4~ group compared with the sham group ([Table 1](#t1-bt_27-222){ref-type="table"}).

Effect of *1,25(OH)~2~D~3~* on intestinal histologic damage in cirrhosis
------------------------------------------------------------------------

HE staining shows that villous height was homogenously distributed with minimal inflammatory cell infiltration in sham rats ([Fig. 2A, 2B](#f2-bt_27-222){ref-type="fig"}). In CCl~4~-treated rats, ileal lymphangiectasia, submucosal cecal edema, and significant inflammatory cell infiltration were observed. However, the intestinal villi of the rats treated with *1,25(OH)~2~D~3~* were more uniform and inflammatory cell infiltration was absent.

Effect of *1,25(OH)~2~D~3~* on intestinal tight junction protein expression
---------------------------------------------------------------------------

In line with the altered intestinal histologic damage, we demonstrated the effects of *1,25(OH)~2~D~3~* on tight junction protein expression. As illustrated in [Fig. 3](#f3-bt_27-222){ref-type="fig"}, western blot analysis and immunofluorescence indicated that *1,25(OH)~2~D~3~* treatment abrogated the CCl~4~-induced loss of ZO-1 and occludin expression in the villi.

Effect of *1,25(OH)~2~D~3~* on intestinal permeability and BT
-------------------------------------------------------------

To determine whether the altered distribution of tight junction proteins induced functional disruption, we utilized biotin as a molecular tracer to assess the integrity of the epithelial barrier. Biotin was found to be restricted solely to the luminal boundary of the colon epithelium in the sham group ([Fig. 4A](#f4-bt_27-222){ref-type="fig"}). In CCl~4~-treated rats, biotin was no longer restricted to the luminal bounder but had permeated the epithelium and extended into the lamina propria. However, the effect was inhibited by treatment with *1,25(OH)~2~D~3~*. *In vivo*, plasma levels of FD4 in CCl~4~-treated rats were significantly increased relative to sham-treated controls. Rats treated with *1,25(OH)~2~D~3~* also displayed a significant reduction in leakage of FD4 across the intestinal wall compared with the CCl~4~ group ([Fig. 4B](#f4-bt_27-222){ref-type="fig"}).

No bacteria was detected in the blood of rats in all groups. BT to MLNs was observed in the sham group. However, the occurrence of BT was increased in MLNs, liver, spleen, and kidney of the CCl~4~-treated rats compared with those of the sham group. *1,25(OH)~2~D~3~* treatment reduced the occurrence of BT during the development of liver cirrhosis in group CCl~4~+*1,25(OH)~2~D~3~*-treated rats ([Table 2](#t2-bt_27-222){ref-type="table"}).

Effect of *1,25(OH)~2~D~3~* on intestinal proliferation, apoptosis, and enterocyte turnover
-------------------------------------------------------------------------------------------

We hypothesized that disequilibrium between proliferation and apoptosis in intestinal epithelial cells would result in intestinal barrier dysfunction. The VDR pathway has been shown to have intestinal protective effects via inhibiting intestinal epithelial apoptosis ([@b3-bt_27-222]; [@b19-bt_27-222]). We demonstrated the effects of *1,25(OH)~2~D~3~* on intestinal proliferation and apoptosis. The activity of *1,25(OH)~2~D~3~* on the proliferation of intestinal cells in mice treated with CCl~4~ was observed by using immunofluorescence of PCNA labeling as well as TUNEL and PCNA double-labeling.

As illustrated in [Fig. 5A](#f5-bt_27-222){ref-type="fig"}, immunofluorescence indicated that CCl~4~ treatment hampered cell proliferation in the small intestinal crypts, and the proliferating crypt cells in CCl~4~-treated rats were shown to be scattered and in disarray. However, *1,25(OH)~2~D~3~* administration restored the proliferative ability of crypt cells in both small intestines and colon ([Fig. 5B, 5C](#f5-bt_27-222){ref-type="fig"}). Meanwhile, we found a markedly greater number of apoptotic cells in the intestinal epithelium of the CCl~4~-treated group than in the sham group, but this was significantly ameliorated by *1,25(OH)~2~D~3~* administration.

Enterocyte migration indicated by BrdU immunopositive cells was found within the basal and middle zone 6 h after BrdU injection ([Fig. 6A](#f6-bt_27-222){ref-type="fig"}). A statistically significant decrease in cell migration was detected in CCl~4~-treated rats, while *1,25(OH)~2~D~3~* administration maintained intestinal epithelial turnover at normal levels ([Fig. 6B](#f6-bt_27-222){ref-type="fig"}).

Effect of *1,25(OH)~2~D~3~* on intestinal HO-1 expression and oxidative stress
------------------------------------------------------------------------------

HO-1 can be induced by inflammatory cytokines, oxidation, ischemia, hypoxia, and endotoxins ([@b11-bt_27-222]). Over-expression of HO-1 promotes intestinal epithelial cell proliferation and migration ([@b23-bt_27-222]). So, we investigated whether the VDR pathway ameliorates intestinal dysfunction by regulating HO-1. HO-1 expression increased slightly in intestinal tissue of CCl~4~-treated rats, but was significantly upregulated by *1,25(OH)~2~D~3~* ([Fig. 7A, 7B](#f7-bt_27-222){ref-type="fig"}). HO-1 and its products exert beneficial effects through protection against oxidative injury, subsequently regulating apoptosis and inflammation. We further studied the effect of *1,25(OH)~2~D~3~* on intestinal oxidative stress ([Fig. 7C--7F](#f7-bt_27-222){ref-type="fig"}).

MDA levels were monitored to evaluate the effect of *1,25(OH)~2~D~3~* treatment on CCl~4~-induced intestinal lipid peroxidation. MDA levels in the CCl~4~ group were significantly higher than those in the sham group. *1,25(OH)~2~D~3~* treatment is known to significantly decrease MDA levels and GSH plays pivotal roles in free radical scavenging and prevention of reactive oxygen species-induced liver damage. GSH levels in the CCl~4~ group were lower than those in the sham group, and GSH levels in the *1,25(OH)~2~D~3~* group were higher than those in the CCl~4~ group.

DISCUSSION
==========

In this study, we found that proliferation and apoptosis of intestinal epithelial cells play critical roles in cirrhosis-associated intestinal mucosal barrier dysfunction. Our results showed that *1,25(OH)~2~D~3~* restored the proliferative ability of crypt cells in the intestines, inhibited enterocyte apoptosis, maintained normal intestinal epithelial turnover, and improved the integrity and function of the intestinal epithelial barrier in CCl~4~-induced liver cirrhotic rats. These beneficial effects can be ascribed, at least in part, to the effect of activation of *1,25(OH)~2~D~3~* on the HO-1 signaling pathway.

BT has been studied in animals subjected to various pathological conditions such as hemorrhagic shock, sepsis, intestinal obstruction, inflammatory bowel disease, acute pancreatitis, and total parenteral nutrition ([@b13-bt_27-222]). Intestinal barrier dysfunction is always associated with cirrhosis and is an important contributor facilitating BT, which has been involved in the pathogenesis of cirrhosis and its complications ([@b22-bt_27-222]; [@b5-bt_27-222]; [@b2-bt_27-222]; [@b16-bt_27-222]). Consistent with previous studies, our findings showed that significant intestinal morphological alterations and tight junction protein loss occurred in CCl~4~-induced liver cirrhotic rats ([@b6-bt_27-222]). Interestingly, ZO-1 and occludin were highly expressed in small bowel than in the colon of the CCl~4~ group. This was different from findings from a previous study and may be related to differing periods of observation ([@b8-bt_27-222]). To determine whether the altered distribution of tight junction proteins induced functional disruption, we also utilized biotin as a molecular tracer to assess the integrity of the epithelial barrier. Biotin permeated the epithelium and extended into the lamina propria. Correspondingly, BT was increased in MLNs, liver, spleen, and kidney in CCl~4~-induced liver cirrhotic rats. However, the above effects were inhibited following treatment with *1,25(OH)~2~D~3~*.

The protective effects of vitamin D have been demonstrated in many organs and tissues besides the gut ([@b24-bt_27-222]). Severe cholestasis leads to vitamin D depletion and vitamin D deficiency promotes cholestatic liver injury ([@b17-bt_27-222]; [@b7-bt_27-222]; [@b12-bt_27-222]). *1,25(OH)~2~D~3~*, the active form of vitamin D, has an antiproliferative and antifibrotic effect on hepatic stellate cells and vitamin D inhibited development of liver fibrosis in an animal model ([@b14-bt_27-222]; [@b1-bt_27-222]). However, the underlying mechanism is not clear. Oxidative stress has been considered to be a major factor in the pathogenesis of hepatic fibrosis ([@b18-bt_27-222]). A recent study indicated that vitamin D appears to act as an antioxidant to protect the rat liver against damage ([@b15-bt_27-222]). In the present study, we confirmed that *1,25(OH)~2~D~3~* treatment also significantly improved intestinal oxidative injury. HO-1, as an Nrf2-dependent gene, exerts beneficial effects through protection against oxidative injury ([@b11-bt_27-222]). In our study, HO-1 expression was significantly diminished in intestinal tissue of CCl~4~-treated rats, but this was reversed by treatment with *1,25(OH)~2~D~3~*. It is worth noting that, regulation of microbial function as well as oxidative stress might both be similarly important targets in the treatment of liver fibrosis and cirrhosis. BT and immune dysfunction have been involved in the pathogenesis of cirrhosis and its complications ([@b22-bt_27-222]; [@b5-bt_27-222]). Our findings suggest that improved intestinal barrier function and diminished BT might contribute to the antifibrotic effect of vitamin D.

The integrity of the intestinal mucosal barrier depends on the balance between epithelial cell proliferation and apoptosis. Strategies to protect mainly the intestinal mucosal barrier could attenuate apoptosis and maintain the proliferative ability of intestinal crypt cells. Our study revealed a significant decrease in cell migration detected in CCl~4~-treated rats; however, *1,25(OH)~2~D~3~* administration maintained intestinal epithelial turnover at normal levels. Accumulating evidence suggests that overexpression of HO-1 promotes intestinal epithelial cell proliferation and migration ([@b20-bt_27-222]; [@b23-bt_27-222]). So, it is speculated that down-regulation of HO-1 is involved in the inhibition of intestinal epithelial proliferation and the apoptosis that occurs with cirrhosis, while *1,25(OH)~2~D~3~* administration induces HO-1 activation and accelerates intestinal epithelial turnover.

The present study has several limitations. Mainly, the assessment of the function of HO-1 and the analysis of loss of inflammation. Although we have observed that HO-1 is involved in intestinal barrier dysfunction in cirrhotic rats, advanced experiments involving HO-1 inhibition or silence are important and can directly elucidate the underlying mechanism.

In conclusion, *1,25(OH)~2~D~3~* has shown significant protective effects in ameliorating intestinal barrier dysfunction in CCl~4~-induced cirrhotic rats. This beneficial effect is chiefly ascribed to its effect on maintenance of intestinal epithelial proliferation and turnover, probably via activation of the HO-1-mediated signaling pathway. Thus, *1,25(OH)~2~D~3~* may represent a new therapeutic agent useful for protection against cirrhosis-associated intestinal barrier dysfunction.
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![*1,25(OH)~2~D~3~* improves liver function and fibrosis in CCl~4~-treated rats. (A) Representative photomicrographs of liver histology (H&E) from each group. (B) Representative photomicrographs of liver histology (Masson's trichrome staining) from each group. (C) Levels of serum ALT, AST, AKP and ALB. ^\*^*p*\<0.05, vs. sham, ^\*\*^*p*\<0.01, vs. sham. ^†^*p*\<0.05, vs. CCl4.](bt_27-222f1){#f1-bt_27-222}

![*1,25(OH)~2~D~3~* maintains intestinal histologic integrity in CCl~4~-treated rats. (A) Representative histological images (H&E staining) of intestine. (B) Representative histological images (H&E staining) of colon.](bt_27-222f2){#f2-bt_27-222}

![*1,25(OH)~2~D~3~* maintains intestinal tight junction expression in CCl~4~-treated rats. (A) ZO-1 and occludin expression in small bowel as determined by immunofluorescence (red), DAPI was used for nuclear labeling. Pictures highlighted in the green box are magnified below. (B) ZO-1 and occludin expression in small bowel as determined by western blot analysis. (C) ZO-1 and occludin expression in colon as determined by western blot analysis. Respective bands with GAPDH as loading control are shown at the bottom of the graphs. ^\*^*p*\<0.05, vs. sham, ^\*\*^*p*\<0.01, vs. sham. ^†^*p*\<0.05, vs. CCl~4~, ^††^*p*\<0.01, vs. CCl~4~.](bt_27-222f3){#f3-bt_27-222}

![*1,25(OH)~2~D~3~* maintains intestinal permeability in CCl~4~ treated rats. (A) Colonic tissues were stained with the molecular tracer biotin to examine barrier permeability. DAPI was used for nuclear labeling. (B) Effects of *1,25(OH)~2~D~3~* on intestinal permeability as measured by FITC-dextran (FD-4)-based intestinal permeability methods. ^\*^*p*\<0.05, vs. sham, ^†^*p*\<0.05, vs. CCl~4~.](bt_27-222f4){#f4-bt_27-222}

![*1,25(OH)~2~D~3~* maintains intestinal proliferation, apoptosis, and enterocyte turnover in CCl4-treated rats. (A) TUNEL (blue) assay with PCNA double-labeling (red) in small bowel as determined by immunofluorescence; DAPI was used for nuclear labeling. (B) Crypt cell proliferation rate and apoptotic index (AI) in small intestine. (C) Crypt cell proliferation rate and apoptotic index (AI) in colon. ^\*^*p*\<0.05, vs. sham, ^\*\*^*p*\<0.01, vs. sham. ^†^*p*\<0.05, vs. CCl~4~.](bt_27-222f5){#f5-bt_27-222}

![*1,25(OH)~2~D~3~* maintains enterocyte turnover in CCl~4~-treated rats. (A) BrdU expression in small intestine 6 h after BrdU injection. (B) Quantification of BrdU+ cells along the crypt-villus axis. ^\*^*p*\<0.05, vs. sham. ^†^*p*\<0.05, vs. CCl~4~.](bt_27-222f6){#f6-bt_27-222}

![*1,25(OH)~2~D~3~* maintains intestinal HO-1 expression and inhibits oxidative stress in CCl~4~-treated rats. (A) HO-1 expression in small bowel and colon as determined by immunofluorescence. (B) HO-1 expression in small bowel and colon as determined by western blot analysis. Respective bands with GAPDH as loading control are shown at the bottom of the graphs. (C--F) MDA levels and GSH levels in small bowel and colon; ^\*^*p*\<0.05, vs. sham, ^\*\*^*p*\<0.01, vs. sham. ^†^*p*\<0.05, vs. CCl~4~, ^††^*p*\<0.01 vs. CCl~4~.](bt_27-222f7){#f7-bt_27-222}

###### 

Serum concentrations of 25-OH vitamin D

  Group   *1,25(OH)~2~D~3~*
  ------- ---------------------------------------------------------
  SHAM    49.4 ± 8.2
  CCL4    36.3 ± 10.1[^\*^](#tfn1-bt_27-222){ref-type="table-fn"}

*p*\<0.05, vs. SHAM.

###### 

Growth of bacterial from harvested samples

  Group                      MLN+                                                Liver+   Slpeen+   Kidney+   Blood+   TR
  -------------------------- --------------------------------------------------- -------- --------- --------- -------- -----------------------------------------------------
  SHAM                       2/8                                                 0/8      0/8       0/8       0/8      5%
  SHAM+*1,25(OH)~2~D~3~*     1/8                                                 0/8      0/8       1/8       0/8      5%
  CCL~4~                     8/8[^\*\*^](#tfn4-bt_27-222){ref-type="table-fn"}   3/8      2/8       4/8       0/8      42.5%[^\*\*^](#tfn4-bt_27-222){ref-type="table-fn"}
  CCL~4~+*1,25(OH)~2~D~3~*   4/8[^&^](#tfn5-bt_27-222){ref-type="table-fn"}      2/8      1/8       2/8       0/8      22.5%[^&^](#tfn5-bt_27-222){ref-type="table-fn"}

+indicates bacterial growth which was considered as evidence of BT.

*p*\<0.05, vs. SHAM,

*p*\<0.01, vs. SHAM.

*p*\<0.05, vs. CCL4.
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